stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Free cash flow margin
MBX Biosciences, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| ADMA ADMA Biologics Inc compare | 27.1% |
| MBX MBX Biosciences, Inc. | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −44.6% |
| XNCR Xencor, Inc. compare | −198.4% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −460.9% |
| RCUS Arcus Biosciences, Inc. compare | −465.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −581.6% |
| CLDX Celldex Therapeutics, Inc. compare | −27,294.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue